Skip to Content

Fortress Biotech Inc FBIO Stock Quote

| Rating as of


Market Open

| Currency in USD

  • Last Close 0.33
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range 0.32  –  0.35
  • Year Range 0.31  –  1.07
  • Market Cap 43.2667 Mil
  • Volume / Avg 173,030.0 /  591,371.2
  • Price / Sales 0.52
  • Price / Book 2.38
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis FBIO

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics FBIO

Company Profile FBIO

Business Description

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

1111 Kane Concourse, Suite 301
Bay Harbor Island, FL, 33154
Industry Biotechnology
Employees 187

Our Quantitative Research team models direct competitors or comparable companies from a bottom-up perspective to find companies describing their business in a similar fashion.

Fortress Biotech Inc


Innovation Pharmaceuticals Inc


Aclaris Therapeutics Inc


Crinetics Pharmaceuticals Inc

−$0.01 (3.58%) $0.00 (0.00%) +$0.12 (1.77%) +$0.38 (1.33%)
Market Cap
43.27 Mil7.78 Mil487.10 Mil1.92 Bil
Biotechnology Biotechnology Diagnostics & Research Biotechnology

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Fortress Biotech Inc Stock

No. FBIO does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

FBIO’s market cap is 43.27 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

FBIO’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

FBIO’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare FBIO’s historical performance against its industry peers and the overall market.